VarmX is a pharmaceutical spin-off from the Leiden University Medical Center (LUMC), founded in 2016, that is specialized in the discovery and development of therapeutic proteins for the prevention and treatment of bleeding. The company’s leading product in development, VMX-C001, is a new therapeutic protein to prevent or stop severe bleeding in patients taking blood thinners in the form of direct factor Xa inhibitors

OnaTherapeutics_logo Portfolio Ysios Capital


VarmX B.V.
Middelweg 38 B
2312 KJ Leiden